There have been two suicides in patients given Acomplia (rimonabant) in obesity studies so far according to an analysis by Arnie Astrup and others from the University of Copenhagen in Frederiksberg, Denmark. One patient was taking 20 mg, while the other patient was taking 5 mg.
This is despite the fact that “[all of] the included trials excluded patients with existing depression, or those with a history [of depression],” Astrup noted.
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.